Schizophrenia

Pharmacists dispensing Lybalvi should understand that potentially life-threatening consequences can occur if opioids are taken concurrently.

Following the success of the phase 3 EMERGENT-2 trial, researchers suggest that xanomeline-trospium could be a safe and effective treatment option for adults with schizophrenia.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.

The mainstay of treatment for schizophrenia and schizoaffective disorder includes antipsychotics.

Study results show that the risk of gaining 10% or more of body weight from the baseline fell 50% when patients were on the combination.

Investigators also report that the therapy could mimic the efficacy of olanzapine but cancelled out the medication-induced weight gain, improving symptoms and outcomes.

Brexpiprazole is indicated as an adjunctive therapy to antidepressants in adults with major depressive disorder and as a treatment in adults with schizophrenia.

Risperidone (Risperdal Consta) is an atypical antipsychotic that can treat schizophrenia, bipolar disorder, and irritability caused by autism.

Aripiprazole Lauroxil (Aristada) is a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults.

Intra Cellular Therapies’ Lumateperone is available in the 10.5- and 21-mg strengths and can also be used to treat depressive episodes associated with bipolar I or II disorder.

Haloperidol (Haldol) is indicated for use in the treatment of schizophrenia and to control the symptoms of Tourette's disorder, as well as severe behavioral problems or hyperactivity in children.

Invega Hafyera is an atypical antipsychotic indicated for the treatment of schizophrenia in adults.

BioXcel plans to launch Igalmi sublingual film in the United States in the second quarter of 2022.

Lumateperone (Caplyta) is used for the treatment of schizophrenia and bipolar depression.

New study results focus on blood pressure, blood sugar, and cholesterol levels; body mass index; and smoking status when individuals have bipolar or schizoaffective disorder or schizophrenia.

The agency previously granted a priority review for the supplemental new drug application and also approved the drug in 2015 to treat adults.

Ten quiz questions to assess your knowledge on common symptoms and treatments for schizophrenia.

Prevalence of type 2 diabetes has been found higher in people with bipolar disorder, schizophrenia, and major depression compared to the general population.

Mean changes from baseline in weight, fasting glucose, total cholesterol, triglycerides, and low-density lipoprotein cholesterol were similar between lumateperone and placebo.

The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.